Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124899 | 0.85 | MAPT (0.54) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL29636216 | 0.84 | HTR1B (0.60) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL290807 | 0.81 | GPR84 (0.53) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL6573798 | 0.81 | MAPT (0.53) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL8489403 | 0.81 | CDK4 (0.65) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL4071924 | 0.80 | SLC6A2 (0.53) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL13253481 | 0.80 | MEN1 (0.55) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL7576426 | 0.79 | MAPT (0.48) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL13735764 | 0.79 | POLB (0.50) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL631077 | 0.79 | MAPT (0.50) | MEN1KMT2AMAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | claimed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | claimed |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2020-03-17 | — | — | US | claimed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-108026049-B | Compositions and methods for treating and preventing neurodegenerative disorders | 阿尔泽恩股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3334710-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | Alzheon, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027582-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | MEN1 2543/4885KMT2A 3173/4885MAPT 12/4885 |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | MEN1 2543/4885KMT2A 3173/4885MAPT 12/4885 |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | MEN1 2543/4885KMT2A 3173/4885MAPT 12/4885 |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | MEN1 2543/4885KMT2A 3173/4885MAPT 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.